+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting PrEP Market - Global Forecast 2026-2032- Product Image
Long-acting PrEP Market - Global Forecast 2026-2032- Product Image
Sale

Long-acting PrEP Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118487
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Long-acting PrEP Market is projected to reach USD 475.10 Million in 2026. It is expected to continue growing at a CAGR of 4.76%, reaching USD 626.06 Million by 2032.

Long-Acting PrEP: Executive Overview of Prevention Innovation

Long-acting pre-exposure prophylaxis (PrEP) is reshaping HIV prevention by reducing reliance on daily pill-taking and offering prevention options administered at longer intervals. Its value is greatest when clinical efficacy is paired with accessible services, reliable follow-up, HIV testing, stigma-sensitive counseling, and systems that support persistence over time. The landscape remains shaped by regulatory decisions, implementation capacity, affordability, community trust, and the ability to reach people who face barriers to daily oral prevention.

From Daily Pills to Flexible, Integrated HIV Prevention

The prevention landscape is shifting toward differentiated service delivery, including injectable and other long-acting approaches alongside oral PrEP, condoms, testing, treatment as prevention, and post-exposure prophylaxis. This transition requires stronger appointment systems, trained providers, cold-chain or product-handling capabilities where relevant, and protocols for managing delayed or missed doses. Successful programs also need to address preferences across populations, protect confidentiality, and avoid treating long-acting PrEP as a standalone intervention detached from broader sexual-health services.

Artificial Intelligence Strengthens Targeting, Follow-Up, and Safety

Artificial intelligence can support long-acting PrEP programs through demand forecasting, appointment reminders, risk-stratified outreach, service-location optimization, multilingual information tools, and analysis of routine program data. Its use should remain clinically governed: algorithms require representative data, privacy safeguards, bias testing, transparent validation, and human review. AI cannot replace HIV testing, clinical assessment, adherence counseling, or informed consent, and systems should be designed to prevent exclusion of people with limited digital access or incomplete health records.

Regional Insights: Uneven Readiness Across Prevention Systems

North America combines established HIV-prevention infrastructure with persistent disparities in access, insurance coverage, and uptake among marginalized communities. Europe benefits from strong public-health systems but faces variation in reimbursement, national guidance, and service integration. Latin America is advancing differentiated prevention while navigating financing, regulatory, and provider-capacity differences. The Middle East requires approaches adapted to legal, cultural, and confidentiality considerations. Africa remains central to global HIV prevention and needs dependable procurement, decentralised delivery, community-led implementation, and sustained workforce support. Asia-Pacific presents diverse epidemics and health systems, making locally tailored delivery, stigma reduction, and cross-border learning particularly important.

Group Insights: Aligning Diverse Blocs Around Prevention Access

ASEAN countries can benefit from regional learning on procurement, differentiated delivery, and services for mobile and key populations, while accounting for substantial policy diversity. BRICS members span major differences in epidemic patterns, health financing, regulatory systems, and domestic manufacturing capabilities, making adaptable implementation models essential. The European Union can use shared evidence standards and cross-border collaboration while retaining national responsibility for reimbursement and service delivery. G7 countries can support evidence generation, equitable financing, and implementation research. GCC settings may prioritize confidential, culturally responsive services and workforce training. NATO members have an opportunity to strengthen interoperable public-health preparedness and prevention access without conflating civilian HIV services with security objectives.

Country Insights: Policy and Delivery Priorities in Fifteen Markets

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States have opportunities to expand access through reimbursement clarity, primary-care integration, and community-led services, while addressing persistent inequities. Brazil and Mexico can build on public-health and community networks by strengthening decentralized delivery, prevention literacy, and continuity of supply. China and India require approaches aligned with large and diverse health systems, regulatory pathways, and targeted outreach. Japan and South Korea may benefit from confidential, stigma-sensitive services and stronger awareness among populations less reached by conventional prevention. Russia’s prevention environment calls for careful attention to testing access, continuity of care, and evidence-based public-health engagement.

Leadership Priorities for Equitable Long-Acting PrEP Implementation

Industry and health-system leaders should establish clear pathways for HIV testing, initiation, maintenance, and management of delayed doses; invest in provider education and community partnerships; and design services around user preferences rather than a single delivery model. Procurement planning should include supply continuity, product storage, and equitable distribution. Decision-makers should track initiation, persistence, missed visits, testing outcomes, adverse events, and access by geography and population group. Transparent value assessment, patient assistance where appropriate, privacy protection, and independent monitoring can help ensure innovation improves prevention without widening existing disparities.

Methodology: Evidence-Based Synthesis of Long-Acting PrEP Dynamics

This executive summary uses a structured synthesis of established clinical, public-health, regulatory, implementation, and health-system considerations relevant to long-acting PrEP. The analysis compares implications across the specified regions, country groupings, and countries, emphasizing documented prevention principles, service-delivery requirements, equity factors, and responsible technology use. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific assessments. Claims should be validated against current national guidance, regulatory records, peer-reviewed evidence, and surveillance data before operational decisions are made.

Conclusion: Turning Long-Acting PrEP Innovation Into Durable Prevention

Long-acting PrEP can broaden HIV-prevention choice and reduce some barriers associated with daily oral medication, but its public-health contribution depends on dependable delivery rather than product availability alone. Leaders should pair innovation with accessible testing, trusted community engagement, inclusive financing, trained providers, resilient supply systems, and rigorous monitoring. Coordinated action across regions, country groups, and national programs can help translate clinical progress into sustained, equitable prevention outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Long-acting PrEP Market, by Product Type
7.1. Introduction
7.2. Implant
7.2.1. Biodegradable
7.2.2. Non-Biodegradable
7.3. Injectable
7.3.1. Intramuscular
7.3.2. Subcutaneous
8. Long-acting PrEP Market, by End User
8.1. Introduction
8.2. Hospitals
8.2.1. Private Hospitals
8.2.2. Public Hospitals
8.3. NGOs
8.3.1. International NGOs
8.3.2. Local NGOs
8.4. Private Clinics
8.4.1. Sexual Health Clinics
8.4.2. STD Clinics
8.5. Public Health Programs
8.5.1. Community Outreach Programs
8.5.2. Government Funded Programs
9. Long-acting PrEP Market, by Administration Setting
9.1. Introduction
9.2. Clinical Setting
9.2.1. Clinic
9.2.2. Hospital
9.3. Home Based
9.3.1. Nurse Assisted Administration
9.3.2. Self Administration
10. Long-acting PrEP Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Long-acting PrEP Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Long-acting PrEP Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Long-acting PrEP Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Accord Healthcare Inc.
15.2. Amneal Pharmaceuticals, Inc.
15.3. Aurobindo Pharma Ltd.
15.4. Cipla Ltd.
15.5. Dr. Reddy's Laboratories Ltd.
15.6. Gilead Sciences, Inc.
15.7. Hetero Labs Limited
15.8. Lupin Limited
15.9. Merck & Co., Inc.
15.10. Mylan N.V.
15.11. Sun Pharmaceutical Industries Ltd.
15.12. Teva Pharmaceutical Industries Ltd.
15.13. Viatris Inc.
15.14. ViiV Healthcare Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Long-acting PrEP Market, Years Considered for the Study
FIGURE 2. Global Long-acting PrEP Market, Research Design
FIGURE 3. Global Long-acting PrEP Market, Research Framework
FIGURE 4. Global Long-acting PrEP Market, Data Triangulation
FIGURE 5. Global Long-acting PrEP Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Long-acting PrEP Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Long-acting PrEP Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Long-acting PrEP Market Size, by End User, 2025 vs 2032 (%)
FIGURE 9. Global Long-acting PrEP Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Long-acting PrEP Market Size, by Administration Setting, 2025 vs 2032 (%)
FIGURE 11. Global Long-acting PrEP Market Size, by Administration Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Long-acting PrEP Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Long-acting PrEP Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Long-acting PrEP Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Long-acting PrEP Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Long-acting PrEP Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Long-acting PrEP Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Long-acting PrEP Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Long-acting PrEP Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Long-acting PrEP Market Segmentation & Coverage
TABLE 2. Global Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 3. Global Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Implant Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Implant Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Implant Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Biodegradable Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Biodegradable Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Biodegradable Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Non-Biodegradable Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Non-Biodegradable Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Non-Biodegradable Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 23. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global NGOs Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global NGOs Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global NGOs Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global International NGOs Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global International NGOs Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global International NGOs Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Local NGOs Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Local NGOs Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Local NGOs Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Private Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Private Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Private Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Sexual Health Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Sexual Health Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Sexual Health Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global STD Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global STD Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global STD Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Public Health Programs Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Public Health Programs Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Public Health Programs Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Community Outreach Programs Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Community Outreach Programs Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Community Outreach Programs Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Government Funded Programs Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Government Funded Programs Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Government Funded Programs Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 60. Global Clinical Setting Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Clinical Setting Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Clinical Setting Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Home Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Home Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Home Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Nurse Assisted Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Nurse Assisted Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Nurse Assisted Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Self Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Self Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Self Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 79. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Long-acting PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Long-acting PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. North America Long-acting PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. North America Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. North America Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 102. North America Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 103. North America Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 104. North America Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 105. North America Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 106. North America Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 107. North America Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 108. North America Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 109. North America Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 110. North America Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 111. North America Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. Latin America Long-acting PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Latin America Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 114. Latin America Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 115. Latin America Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 116. Latin America Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Latin America Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 118. Latin America Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 119. Latin America Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 120. Latin America Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 121. Latin America Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 122. Latin America Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 123. Latin America Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 124. Latin America Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 125. Europe Long-acting PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Europe Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. Europe Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 128. Europe Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 129. Europe Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. Europe Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 131. Europe Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 132. Europe Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 133. Europe Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 134. Europe Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 135. Europe Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 136. Europe Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 137. Europe Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 138. Middle East Long-acting PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Middle East Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 140. Middle East Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 141. Middle East Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 142. Middle East Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Middle East Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 144. Middle East Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 145. Middle East Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 146. Middle East Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 147. Middle East Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 148. Middle East Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 149. Middle East Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 150. Middle East Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. Africa Long-acting PrEP Market Size, by Region, 2017-2032 (USD Million)
TABLE 152. Africa Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 153. Africa Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 154. Africa Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 155. Africa Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. Africa Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 157. Africa Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 158. Africa Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 159. Africa Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 160. Africa Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 161. Africa Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 162. Africa Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 163. Africa Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. Global Long-acting PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. ASEAN Long-acting PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. ASEAN Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 167. ASEAN Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 168. ASEAN Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 169. ASEAN Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 170. ASEAN Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 171. ASEAN Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 172. ASEAN Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 173. ASEAN Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 174. ASEAN Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 175. ASEAN Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 176. ASEAN Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 177. ASEAN Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. GCC Long-acting PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. GCC Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 180. GCC Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 181. GCC Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 182. GCC Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. GCC Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 184. GCC Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 185. GCC Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 186. GCC Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 187. GCC Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 188. GCC Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 189. GCC Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 190. GCC Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. European Union Long-acting PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 192. European Union Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 193. European Union Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 194. European Union Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 195. European Union Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 196. European Union Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 197. European Union Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 198. European Union Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 199. European Union Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 200. European Union Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 201. European Union Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 202. European Union Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 203. European Union Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. BRICS Long-acting PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 205. BRICS Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 206. BRICS Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 207. BRICS Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 208. BRICS Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. BRICS Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 210. BRICS Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 211. BRICS Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 212. BRICS Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 213. BRICS Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 214. BRICS Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 215. BRICS Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 216. BRICS Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. G7 Long-acting PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. G7 Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. G7 Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 220. G7 Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 221. G7 Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. G7 Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 223. G7 Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 224. G7 Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 225. G7 Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 226. G7 Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 227. G7 Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 228. G7 Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 229. G7 Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. NATO Long-acting PrEP Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. NATO Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 232. NATO Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 233. NATO Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 234. NATO Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. NATO Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 236. NATO Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 237. NATO Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 238. NATO Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 239. NATO Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 240. NATO Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 241. NATO Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 242. NATO Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. Global Long-acting PrEP Market Size, by Country, 2017-2032 (USD Million)
TABLE 244. United States Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 245. United States Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 246. United States Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 247. United States Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 248. United States Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. United States Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 250. United States Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 251. United States Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 252. United States Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 253. United States Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 254. United States Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 255. United States Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 256. United States Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 257. Canada Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 258. Canada Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 259. Canada Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 260. Canada Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 261. Canada Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. Canada Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 263. Canada Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 264. Canada Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 265. Canada Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 266. Canada Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 267. Canada Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 268. Canada Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 269. Canada Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 270. Mexico Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 271. Mexico Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 272. Mexico Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 273. Mexico Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 274. Mexico Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Mexico Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 276. Mexico Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 277. Mexico Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 278. Mexico Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 279. Mexico Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 280. Mexico Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 281. Mexico Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 282. Mexico Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 283. Brazil Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 284. Brazil Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 285. Brazil Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 286. Brazil Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 287. Brazil Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 288. Brazil Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 289. Brazil Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 290. Brazil Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 291. Brazil Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 292. Brazil Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 293. Brazil Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 294. Brazil Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 295. Brazil Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 296. United Kingdom Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 297. United Kingdom Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 298. United Kingdom Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 299. United Kingdom Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 300. United Kingdom Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. United Kingdom Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 302. United Kingdom Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 303. United Kingdom Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 304. United Kingdom Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 305. United Kingdom Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 306. United Kingdom Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 307. United Kingdom Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 308. United Kingdom Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 309. Germany Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 310. Germany Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 311. Germany Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 312. Germany Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 313. Germany Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. Germany Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 315. Germany Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 316. Germany Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 317. Germany Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 318. Germany Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 319. Germany Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 320. Germany Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 321. Germany Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 322. France Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 323. France Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 324. France Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 325. France Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 326. France Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 327. France Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 328. France Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 329. France Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 330. France Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 331. France Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 332. France Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 333. France Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 334. France Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. Russia Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 336. Russia Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 337. Russia Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 338. Russia Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 339. Russia Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 340. Russia Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 341. Russia Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 342. Russia Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 343. Russia Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 344. Russia Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 345. Russia Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 346. Russia Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 347. Russia Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 348. Italy Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 349. Italy Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 350. Italy Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 351. Italy Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 352. Italy Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 353. Italy Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 354. Italy Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 355. Italy Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 356. Italy Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 357. Italy Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 358. Italy Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 359. Italy Long-acting PrEP Market Size, by Home Based, 2017-2032 (USD Million)
TABLE 360. Italy Long-acting PrEP Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 361. Spain Long-acting PrEP Market Size, 2017-2032 (USD Million)
TABLE 362. Spain Long-acting PrEP Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 363. Spain Long-acting PrEP Market Size, by Implant, 2017-2032 (USD Million)
TABLE 364. Spain Long-acting PrEP Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 365. Spain Long-acting PrEP Market Size, by End User, 2017-2032 (USD Million)
TABLE 366. Spain Long-acting PrEP Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 367. Spain Long-acting PrEP Market Size, by NGOs, 2017-2032 (USD Million)
TABLE 368. Spain Long-acting PrEP Market Size, by Private Clinics, 2017-2032 (USD Million)
TABLE 369. Spain Long-acting PrEP Market Size, by Public Health Programs, 2017-2032 (USD Million)
TABLE 370. Spain Long-acting PrEP Market Size, by Administration Setting, 2017-2032 (USD Million)
TABLE 371. Spain Long-acting PrEP Market Size, by Clinical Setting, 2017-2032 (USD Million)
TABLE 372. Spain Long-acting PrEP Market Size, by

Companies Mentioned

  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited

Related Topics

Related Reports

Prophylactic HIV Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Prophylactic HIV Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Pre-Exposure Prophylaxis Market - Global Forecast 2026-2032 - Product Image

Pre-Exposure Prophylaxis Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis - Update - Product Image

Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast and Market Analysis - Update

  • Report
  • 177 Pages
  • Global
From
Anti-Retroviral Drugs - Global Strategic Business Report - Product Image

Anti-Retroviral Drugs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Integrase Inhibitors Market - Global Strategic Business Report - Product Image

Integrase Inhibitors Market - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.